Cargando…
FcRn-Dependent Transcytosis of Monoclonal Antibody in Human Nasal Epithelial Cells In Vitro: A Prerequisite for a New Delivery Route for Therapy?
Monoclonal antibodies (mAbs) are promising therapies to treat airway chronic inflammatory disease (asthma or nasal polyps). To date, no study has specifically assessed, in vitro, the potential function of neonatal Fc receptor (FcRn) in IgG transcytosis through the human nasal airway epithelium. The...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470570/ https://www.ncbi.nlm.nih.gov/pubmed/30893823 http://dx.doi.org/10.3390/ijms20061379 |
_version_ | 1783411827809452032 |
---|---|
author | Bequignon, Emilie Dhommée, Christine Angely, Christelle Thomas, Lucie Bottier, Mathieu Escudier, Estelle Isabey, Daniel Coste, André Louis, Bruno Papon, Jean-François Gouilleux-Gruart, Valérie |
author_facet | Bequignon, Emilie Dhommée, Christine Angely, Christelle Thomas, Lucie Bottier, Mathieu Escudier, Estelle Isabey, Daniel Coste, André Louis, Bruno Papon, Jean-François Gouilleux-Gruart, Valérie |
author_sort | Bequignon, Emilie |
collection | PubMed |
description | Monoclonal antibodies (mAbs) are promising therapies to treat airway chronic inflammatory disease (asthma or nasal polyps). To date, no study has specifically assessed, in vitro, the potential function of neonatal Fc receptor (FcRn) in IgG transcytosis through the human nasal airway epithelium. The objective of this study was to report the in vitro expression and function of FcRn in nasal human epithelium. FcRn expression was studied in an air–liquid interface (ALI) primary culture model of human nasal epithelial cells (HNEC) from polyps. FcRn expression was characterized by quantitative RT-PCR, western blot, and immunolabeling. The ability of HNECs to support mAb transcytosis via FcRn was assessed by transcytosis assay. This study demonstrates the expression of FcRn mRNA and protein in HNEC. We report a high expression of FcRn in the cytosol of ciliated, mucus, and basal cells by immunohistochemistry with a higher level of FcRn proteins in differentiated HNEC. We also proved in vitro transepithelial delivery of an IgG1 therapeutic mAb with a dose–response curve. This is the first time that FcRn expression and mAb transcytosis has been shown in a model of human nasal respiratory epithelium in vitro. This study is a prerequisite for FcRn-dependent nasal administration of mAbs. |
format | Online Article Text |
id | pubmed-6470570 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64705702019-04-26 FcRn-Dependent Transcytosis of Monoclonal Antibody in Human Nasal Epithelial Cells In Vitro: A Prerequisite for a New Delivery Route for Therapy? Bequignon, Emilie Dhommée, Christine Angely, Christelle Thomas, Lucie Bottier, Mathieu Escudier, Estelle Isabey, Daniel Coste, André Louis, Bruno Papon, Jean-François Gouilleux-Gruart, Valérie Int J Mol Sci Article Monoclonal antibodies (mAbs) are promising therapies to treat airway chronic inflammatory disease (asthma or nasal polyps). To date, no study has specifically assessed, in vitro, the potential function of neonatal Fc receptor (FcRn) in IgG transcytosis through the human nasal airway epithelium. The objective of this study was to report the in vitro expression and function of FcRn in nasal human epithelium. FcRn expression was studied in an air–liquid interface (ALI) primary culture model of human nasal epithelial cells (HNEC) from polyps. FcRn expression was characterized by quantitative RT-PCR, western blot, and immunolabeling. The ability of HNECs to support mAb transcytosis via FcRn was assessed by transcytosis assay. This study demonstrates the expression of FcRn mRNA and protein in HNEC. We report a high expression of FcRn in the cytosol of ciliated, mucus, and basal cells by immunohistochemistry with a higher level of FcRn proteins in differentiated HNEC. We also proved in vitro transepithelial delivery of an IgG1 therapeutic mAb with a dose–response curve. This is the first time that FcRn expression and mAb transcytosis has been shown in a model of human nasal respiratory epithelium in vitro. This study is a prerequisite for FcRn-dependent nasal administration of mAbs. MDPI 2019-03-19 /pmc/articles/PMC6470570/ /pubmed/30893823 http://dx.doi.org/10.3390/ijms20061379 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bequignon, Emilie Dhommée, Christine Angely, Christelle Thomas, Lucie Bottier, Mathieu Escudier, Estelle Isabey, Daniel Coste, André Louis, Bruno Papon, Jean-François Gouilleux-Gruart, Valérie FcRn-Dependent Transcytosis of Monoclonal Antibody in Human Nasal Epithelial Cells In Vitro: A Prerequisite for a New Delivery Route for Therapy? |
title | FcRn-Dependent Transcytosis of Monoclonal Antibody in Human Nasal Epithelial Cells In Vitro: A Prerequisite for a New Delivery Route for Therapy? |
title_full | FcRn-Dependent Transcytosis of Monoclonal Antibody in Human Nasal Epithelial Cells In Vitro: A Prerequisite for a New Delivery Route for Therapy? |
title_fullStr | FcRn-Dependent Transcytosis of Monoclonal Antibody in Human Nasal Epithelial Cells In Vitro: A Prerequisite for a New Delivery Route for Therapy? |
title_full_unstemmed | FcRn-Dependent Transcytosis of Monoclonal Antibody in Human Nasal Epithelial Cells In Vitro: A Prerequisite for a New Delivery Route for Therapy? |
title_short | FcRn-Dependent Transcytosis of Monoclonal Antibody in Human Nasal Epithelial Cells In Vitro: A Prerequisite for a New Delivery Route for Therapy? |
title_sort | fcrn-dependent transcytosis of monoclonal antibody in human nasal epithelial cells in vitro: a prerequisite for a new delivery route for therapy? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470570/ https://www.ncbi.nlm.nih.gov/pubmed/30893823 http://dx.doi.org/10.3390/ijms20061379 |
work_keys_str_mv | AT bequignonemilie fcrndependenttranscytosisofmonoclonalantibodyinhumannasalepithelialcellsinvitroaprerequisiteforanewdeliveryroutefortherapy AT dhommeechristine fcrndependenttranscytosisofmonoclonalantibodyinhumannasalepithelialcellsinvitroaprerequisiteforanewdeliveryroutefortherapy AT angelychristelle fcrndependenttranscytosisofmonoclonalantibodyinhumannasalepithelialcellsinvitroaprerequisiteforanewdeliveryroutefortherapy AT thomaslucie fcrndependenttranscytosisofmonoclonalantibodyinhumannasalepithelialcellsinvitroaprerequisiteforanewdeliveryroutefortherapy AT bottiermathieu fcrndependenttranscytosisofmonoclonalantibodyinhumannasalepithelialcellsinvitroaprerequisiteforanewdeliveryroutefortherapy AT escudierestelle fcrndependenttranscytosisofmonoclonalantibodyinhumannasalepithelialcellsinvitroaprerequisiteforanewdeliveryroutefortherapy AT isabeydaniel fcrndependenttranscytosisofmonoclonalantibodyinhumannasalepithelialcellsinvitroaprerequisiteforanewdeliveryroutefortherapy AT costeandre fcrndependenttranscytosisofmonoclonalantibodyinhumannasalepithelialcellsinvitroaprerequisiteforanewdeliveryroutefortherapy AT louisbruno fcrndependenttranscytosisofmonoclonalantibodyinhumannasalepithelialcellsinvitroaprerequisiteforanewdeliveryroutefortherapy AT paponjeanfrancois fcrndependenttranscytosisofmonoclonalantibodyinhumannasalepithelialcellsinvitroaprerequisiteforanewdeliveryroutefortherapy AT gouilleuxgruartvalerie fcrndependenttranscytosisofmonoclonalantibodyinhumannasalepithelialcellsinvitroaprerequisiteforanewdeliveryroutefortherapy |